Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) have been given a consensus recommendation of “Hold” by the twelve brokerages that are presently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $8.1250.

Several equities analysts have recently commented on NMRA shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neumora Therapeutics in a research report on Wednesday, October 8th. Mizuho set a $6.00 target price on Neumora Therapeutics in a report on Monday, January 5th. Guggenheim upgraded Neumora Therapeutics from a “neutral” rating to a “buy” rating and set a $14.00 price target for the company in a report on Monday, October 27th. Leerink Partnrs raised Neumora Therapeutics to a “strong-buy” rating in a research report on Monday, January 12th. Finally, Royal Bank Of Canada raised shares of Neumora Therapeutics from a “sector perform” rating to an “outperform” rating and lifted their price objective for the stock from $4.00 to $7.00 in a report on Monday, December 1st.

Neumora Therapeutics Stock Down 5.2%

Shares of NASDAQ:NMRA opened at $2.02 on Monday. The firm has a market cap of $337.52 million, a PE ratio of -1.37 and a beta of 3.22. The company has a fifty day simple moving average of $2.14 and a 200 day simple moving average of $1.91. The company has a current ratio of 6.85, a quick ratio of 6.85 and a debt-to-equity ratio of 0.15. Neumora Therapeutics has a 12-month low of $0.61 and a 12-month high of $3.25.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). On average, equities research analysts anticipate that Neumora Therapeutics will post -1.61 EPS for the current fiscal year.

Insider Activity

In other Neumora Therapeutics news, insider Daljit Singh Aurora sold 114,703 shares of the firm’s stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $2.68, for a total value of $307,404.04. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Arch Venture Partners Xii, Llc bought 1,915,700 shares of the firm’s stock in a transaction on Monday, October 27th. The stock was bought at an average price of $2.61 per share, with a total value of $4,999,977.00. Following the completion of the purchase, the insider owned 6,046,907 shares of the company’s stock, valued at $15,782,427.27. This trade represents a 46.37% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Company insiders own 26.80% of the company’s stock.

Institutional Trading of Neumora Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in NMRA. Millennium Management LLC boosted its position in Neumora Therapeutics by 63.1% during the 3rd quarter. Millennium Management LLC now owns 2,008,248 shares of the company’s stock valued at $3,655,000 after purchasing an additional 776,856 shares during the period. Jacobs Levy Equity Management Inc. bought a new stake in Neumora Therapeutics in the third quarter valued at $1,512,000. AlphaCore Capital LLC boosted its holdings in shares of Neumora Therapeutics by 89.1% during the third quarter. AlphaCore Capital LLC now owns 638,784 shares of the company’s stock valued at $1,163,000 after acquiring an additional 301,017 shares during the period. AQR Capital Management LLC bought a new position in shares of Neumora Therapeutics during the first quarter worth about $463,000. Finally, Cerity Partners LLC increased its holdings in shares of Neumora Therapeutics by 7.2% in the 2nd quarter. Cerity Partners LLC now owns 324,219 shares of the company’s stock worth $238,000 after acquiring an additional 21,714 shares during the period. 47.65% of the stock is currently owned by institutional investors and hedge funds.

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.